HOOK HOOKIPA Pharma
- 0.766
- -0.002-0.22%
- 0.752
- -0.014-1.87%
HOOKIPA Pharma News
HOOKIPA Pharma First Quarter 2024 Earnings: Beats Expectations
RBC Capital Initiates a Buy Rating on Hookipa Pharma (HOOK)
Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK) and Femasys (FEMY)
HOOKIPA Pharma | 10-Q: Quarterly report
HOOKIPA Pharma 1Q EPS 11c >HOOK
HOOKIPA Pharma 1Q EPS 11c >HOOK
Press Release: HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights -- Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), BioMarin Pharmaceutical (BMRN) and Hookipa Pharma (HOOK)
HOOKIPA Pharma Inc. (NASDAQ:HOOK) Stock Catapults 25% Though Its Price And Business Still Lag The Industry
Despite an already strong run, HOOKIPA Pharma Inc. (NASDAQ:HOOK) shares have been powering on, with a gain of 25% in the last thirty days. Unfortunately, the gains of the last month did little to r
HOOKIPA Pharma Price Target Cut to $5.00/Share From $6.50 by HC Wainwright & Co.
HOOKIPA Pharma Price Target Cut to $5.00/Share From $6.50 by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on HOOKIPA Pharma, Lowers Price Target to $5
HC Wainwright & Co. analyst Arthur He maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Buy and lowers the price target from $6.5 to $5.
Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK), Praxis Precision Medicines (PRAX) and Blueprint Medicines (BPMC)
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination With Pembrolizumab
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for
Buy Rating Affirmed for Hookipa Pharma Amidst Promising Pipeline and Strategic Advancements
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?
HOOKIPA Pharma Shares Are Trading Higher After the Company Received FDA Clearance for Its IND Application for HB-700.
HOOKIPA Pharma Shares Are Trading Higher After the Company Received FDA Clearance for Its IND Application for HB-700.
HOOKIPA Pharma Announces FDA Clearance of Its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
NEW YORK and VIENNA, Austria, April 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, 'HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and VIENNA, Austria, April 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, 'HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of HOOKIPA Pharma Inc. (HOOK) and Encourages Long-Term Investors to Contact the Firm
Philadelphia, Pennsylvania--(Newsfile Corp. - April 15, 2024) - Kaskela Law LLC announces that it is investigating HOOKIPA Pharma Inc. (NASDAQ: HOOK) on behalf of the company's long-term investors. Th
HOOKIPA Pharma Announced That Members Of Its Executive Team Will Host An Investor Call Summarizing The Company's Constructive Regulatory Interactions With The U.S. Food & Drug Administration (FDA) And The European Medicines Agency (EMA)
HOOKIPA Pharma Announced That Members Of Its Executive Team Will Host An Investor Call Summarizing The Company's Constructive Regulatory Interactions With The U.S. Food & Drug Administration (FDA) And
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
HOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with pembrolizumabHB-200 program receives Priority Medicines (PRIME) designation from EMA NEW YORK and VIENNA, Austria,
Analysis
Price Target
No Data
